(NASDAQ: HUMA) Humacyte's forecast annual revenue growth rate of 355.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Humacyte's revenue in 2025 is $818,000.On average, 2 Wall Street analysts forecast HUMA's revenue for 2025 to be $555,094,466, with the lowest HUMA revenue forecast at $479,867,684, and the highest HUMA revenue forecast at $630,321,249. On average, 2 Wall Street analysts forecast HUMA's revenue for 2026 to be $4,747,997,747, with the lowest HUMA revenue forecast at $2,427,845,412, and the highest HUMA revenue forecast at $7,068,150,081.
In 2027, HUMA is forecast to generate $12,888,327,439 in revenue, with the lowest revenue forecast at $11,385,375,517 and the highest revenue forecast at $14,391,279,361.